Search





Search





Markets
/
Stocks
/
dsgn
/

Design Therapeutics Inc

DSGN

Add to Watchlist

12.010USD

-0.170-1.40%

Close 07-31 16:00（ET）Quotes delayed by 15 min

749.92MMarket Cap

LossP/E TTM

Design Therapeutics Inc

12.010

-0.170-1.40%

Financial Summary Income Statement Balance Sheet Cash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial Summary Income Statement Balance Sheet Cash Flow Statement

DSGN Cash Flow Statement

You can access the annual and quarterly cash flow statements of Design Therapeutics Inc to evaluate its financial soundness and stability.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021Q4

FY2021Q3

FY2021Q2

FY2021Q1

Operating cash flows (indirect method)

Cash flow from continuing operating activities

2.13%-16.43M

-21.36%-11.97M

-16.93%-11.16M

-28.25%-14.44M

-34.97%-16.79M

22.96%-9.86M

34.32%-9.55M

18.43%-11.26M

28.61%-12.44M

15.19%-12.80M

-4.57%-14.53M

-31.47%-13.80M

-47.32%-17.42M

-63.55%-15.09M

-70.25%-13.90M

-26.67%-10.50M

-219.91%-11.83M

---9.23M

---8.16M

---8.29M

---3.70M

Net income from continuing operations

0.45%-17.64M

-17.19%-16.00M

-30.36%-17.00M

-61.82%-19.08M

-59.52%-17.71M

-15.28%-13.65M

17.42%-13.04M

40.85%-11.79M

42.44%-11.11M

31.71%-11.84M

10.82%-15.79M

-32.92%-19.94M

-45.45%-19.29M

-56.71%-17.34M

-56.42%-17.70M

-96.42%-15.00M

-140.57%-13.27M

---11.06M

---11.32M

---7.64M

---5.51M

Operating gains losses

-1.26%157.00K

4.70%156.00K

1.31%155.00K

0.66%152.00K

11.19%159.00K

7.97%149.00K

11.68%153.00K

13.53%151.00K

10.85%143.00K

11.29%138.00K

26.85%137.00K

44.57%133.00K

57.32%129.00K

51.22%124.00K

248.39%108.00K

666.67%92.00K

1950.00%82.00K

--82.00K

--31.00K

--12.00K

--4.00K

Other non-cash items

92.67%-78.00K

63.91%-520.00K

46.80%-774.00K

68.83%-489.00K

38.39%-1.06M

21.30%-1.44M

14.46%-1.46M

-13.12%-1.57M

-52.56%-1.73M

-93.14%-1.83M

-283.11%-1.70M

-4103.03%-1.39M

-3530.30%-1.13M

-4614.29%-948.00K

-1368.57%-444.00K

-250.00%-33.00K

122.00%33.00K

--21.00K

--35.00K

--22.00K

---150.00K

Change in working capital

-63.82%-2.80M

-40.45%960.00K

70.78%2.86M

173.74%994.00K

41.79%-1.71M

181.13%1.61M

519.25%1.68M

-136.75%-1.35M

-430.56%-2.93M

-66133.33%-1.99M

-131.52%-400.00K

101.21%3.67M

46.67%-553.00K

-101.68%-3.00K

-31.22%1.27M

194.46%1.82M

-178.80%-1.04M

--179.00K

--1.84M

---1.93M

--1.32M

-Change in prepaid expenses

79.60%-287.00K

-245.45%-880.00K

-30.45%459.00K

171.97%452.00K

-242.34%-1.41M

-26.49%605.00K

203.29%660.00K

-205.02%-628.00K

-134.48%-411.00K

274.73%823.00K

66.40%-639.00K

175.58%598.00K

196.36%1.19M

-334.33%-471.00K

-508.15%-1.90M

113.36%217.00K

-1961.67%-1.24M

--201.00K

--466.00K

---1.62M

---60.00K

-Change in payables and accrued expense

-734.22%-2.51M

82.72%1.84M

136.48%2.40M

175.28%542.00K

88.07%-301.00K

135.84%1.01M

325.52%1.02M

-123.45%-720.00K

-44.58%-2.52M

-788.73%-2.81M

-92.46%239.00K

91.16%3.07M

-972.50%-1.75M

1095.12%408.00K

129.95%3.17M

633.55%1.61M

-85.47%200.00K

---41.00K

--1.38M

---301.00K

--1.38M

-Change in other current liabilities

----

--0.00

---5.00K

--0.00

Cash from non-recurring investing activities

Cash from operating activities

2.13%-16.43M

-21.36%-11.97M

-16.93%-11.16M

-28.25%-14.44M

-34.97%-16.79M

22.96%-9.86M

34.32%-9.55M

18.43%-11.26M

28.61%-12.44M

15.19%-12.80M

-4.57%-14.53M

-31.47%-13.80M

-47.32%-17.42M

-63.55%-15.09M

-70.25%-13.90M

-26.67%-10.50M

-219.91%-11.83M

---9.23M

---8.16M

---8.29M

---3.70M

Investing cash flow

Net cash from continuing investing activities

-100.00%0.00

--34.00K

100.00%0.00

-45.96%87.00K

-63.08%72.00K

-100.00%0.00

-130.19%-16.00K

80.90%161.00K

124.14%195.00K

-90.63%27.00K

-82.90%53.00K

-56.59%89.00K

14.47%87.00K

-18.64%288.00K

-67.98%310.00K

12.02%205.00K

130.30%76.00K

--354.00K

--968.00K

--183.00K

--33.00K

Capital expenditures

-100.00%0.00

--34.00K

--0.00

-45.96%87.00K

-63.08%72.00K

-100.00%0.00

----

80.90%161.00K

124.14%195.00K

-90.63%27.00K

-82.90%53.00K

-63.52%89.00K

14.47%87.00K

-18.64%288.00K

-67.98%310.00K

33.33%244.00K

130.30%76.00K

--354.00K

--968.00K

--183.00K

--33.00K

Net cash flow from disposal of fixed assets

-100.00%0.00

--34.00K

100.00%0.00

-45.96%87.00K

-63.08%72.00K

-100.00%0.00

-130.19%-16.00K

80.90%161.00K

124.14%195.00K

-90.63%27.00K

-82.90%53.00K

-56.59%89.00K

14.47%87.00K

-18.64%288.00K

-67.98%310.00K

12.02%205.00K

130.30%76.00K

--354.00K

--968.00K

--183.00K

--33.00K

Net cash flow from investment products

-195.56%-7.59M

-730.40%-11.55M

211.43%6.51M

-26.52%20.20M

-61.84%7.94M

-67.18%1.83M

-138.14%-5.84M

127.77%27.49M

5.00%20.81M

826.82%5.58M

124.29%15.32M

107.70%12.07M

3944.90%19.82M

98.45%-768.00K

-1448.33%-63.08M

-632.89%-156.75M

-97.88%490.00K

---49.70M

---4.07M

---21.39M

--23.06M

Net cash flow from other investing activities

--0.00

----

--0.00

----

Cash from non-current investing activities

Net cash flow from investing activities

-196.43%-7.59M

-732.26%-11.58M

211.74%6.51M

-26.40%20.12M

-61.83%7.87M

-67.02%1.83M

-138.16%-5.83M

128.12%27.33M

4.47%20.62M

626.04%5.55M

124.08%15.27M

107.63%11.98M

4666.43%19.73M

97.89%-1.06M

-1157.22%-63.39M

-627.63%-156.96M

-98.20%414.00K

---50.06M

---5.04M

---21.57M

--23.03M

Financing cash flow

Cash flow from continuous financing activities

86569.57%19.93M

9526.24%25.32M

3600.00%37.00K

57.64%361.00K

15.00%23.00K

-47.50%263.00K

-92.31%1.00K

9.05%229.00K

--20.00K

285.38%501.00K

-91.39%13.00K

203.96%210.00K

-100.00%0.00

-32.64%130.00K

403.33%151.00K

-4140.00%-202.00K

-99.96%156.00K

--193.00K

--30.00K

--5.00K

--378.98M

Net cash flow from debt Issuance/repayment

----

--0.00

Net cash flow from common stock issuance/repurchase

--19.91M

--24.85M

----

--0.00

-100.00%0.00

--0.00

--254.27M

Net cash flow from preferred stock issuance/repurchase

----

--0.00

-100.00%0.00

--0.00

--124.71M

Proceeds from stock option exercised by employees

17.39%27.00K

78.71%470.00K

3600.00%37.00K

57.64%361.00K

15.00%23.00K

-47.50%263.00K

-92.31%1.00K

9.05%229.00K

--20.00K

285.38%501.00K

-91.39%13.00K

-6.67%210.00K

-100.00%0.00

-32.64%130.00K

403.33%151.00K

4400.00%225.00K

--156.00K

--193.00K

--30.00K

--5.00K

----

Net cash flow from other financing activities

--0.00

----

--0.00

----

--0.00

----

--0.00

---427.00K

----

Net cash from non-recurrent financing activities

Net cash from financing activities

86569.57%19.93M

9526.24%25.32M

3600.00%37.00K

57.64%361.00K

15.00%23.00K

-47.50%263.00K

-92.31%1.00K

9.05%229.00K

--20.00K

285.38%501.00K

-91.39%13.00K

203.96%210.00K

-100.00%0.00

-32.64%130.00K

403.33%151.00K

-4140.00%-202.00K

-99.96%156.00K

--193.00K

--30.00K

--5.00K

--378.98M

Net cash flow

Beginning cash balance

-25.29%16.86M

-50.25%15.09M

-56.89%19.70M

-53.51%13.67M

6.43%22.56M

8.54%30.33M

68.03%45.70M

2.04%29.40M

-20.00%21.20M

-34.28%27.94M

-77.27%27.20M

-89.97%28.81M

-91.12%26.50M

-88.11%42.52M

-67.73%119.65M

-28.30%287.31M

12450.19%298.57M

--357.66M

--370.84M

--400.69M

--2.38M

Current period cash flow changes

54.07%-4.09M

122.77%1.77M

69.98%-4.62M

-62.97%6.04M

-208.53%-8.90M

-15.17%-7.76M

-2163.22%-15.37M

1111.29%16.30M

255.00%8.20M

57.91%-6.74M

100.97%745.00K

99.04%-1.61M

120.51%2.31M

72.90%-16.02M

-485.44%-77.14M

-461.57%-167.66M

-102.83%-11.26M

---59.09M

---13.18M

---29.86M

--398.31M

Ending cash balance

-6.56%12.77M

-25.29%16.86M

-50.25%15.09M

-56.89%19.70M

-53.51%13.67M

6.43%22.56M

8.54%30.33M

68.03%45.70M

2.04%29.40M

-20.00%21.20M

-34.28%27.94M

-77.27%27.20M

-89.97%28.81M

-91.12%26.50M

-88.11%42.52M

-67.73%119.65M

-28.30%287.31M

--298.57M

--357.66M

--370.84M

--400.69M

Free cash flow

2.55%-16.43M

-21.70%-12.00M

-16.93%-11.16M

-27.20%-14.53M

-33.46%-16.86M

23.12%-9.86M

34.56%-9.55M

17.79%-11.42M

27.85%-12.63M

16.61%-12.82M

-2.66%-14.59M

-29.31%-13.89M

-47.11%-17.51M

-60.52%-15.38M

-55.60%-14.21M

-26.82%-10.74M

-219.12%-11.90M

---9.58M

---9.13M

---8.47M

---3.73M

Currency unit

--USD

Audit opinions

----

FAQs

What is operating cash flow?



Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did Design Therapeutics Inc Generate?



Design Therapeutics Inc generated -54.36M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did Design Therapeutics Inc's Operating Cash Flow Change Year Over Year?



Design Therapeutics Inc's operating cash flow increased by -26.11% year over year.

What is investing cash flow?



Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does Design Therapeutics Inc Spend on Capital Expenditures?



Design Therapeutics Inc spent 193.00K on capital expenditures in the most recent quarter。

What is financing cash flow?



Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has Design Therapeutics Inc's Financing Cash Flow Changed?



Design Therapeutics Inc used 25.74M in financing activities in the latest quarter.

What is free cash flow and why does it matter for DSGN?



Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was Design Therapeutics Inc’s free cash flow in the latest quarter?



Free cash flow was -54.55M reflecting a -25.56% change from the previous year.